Two-year Bimzelx data demonstrate sustained disease control in HS

Belgium’s largest drugmaker UCB (Euronext: UCB) today released long-term data from the BE HEARD^ trials for Bimzelx (bimekizumab) in moderate to severe hidradenitis suppurativa (HS). These two-year data, building on the established efficacy profile of bimekizumab in HS, showcase that its unique dual inhibition offers a durable treatment option for this challenging, chronic skin condition.

After two years of bimekizumab treatment, 53.1% of patients had mild disease compared to 0.0% at baseline. At two years, 83.4% of patients with hidradenitis suppurativa remained flare-free, while 86.9% of HiSCR75 responders to bimekizumab at 48 weeks maintained this response

“For people living with HS, draining tunnels associated with moderate and severe disease can be incredibly distressing and painful – often derailing daily life,” said Professor Christos Zouboulis, president of the European Hidradenitis Suppurativa Foundation (EHSF) eV, director of the Departments of Dermatology, Venereology, Allergology and Immunology, Städtisches Klinikum Dessau, and Founding Professor of Dermatology and Venereology at the Brandenburg Medical School, Germany. “These new, specific two-year data demonstrate bimekizumab’s ability to provide sustained disease control, meaning a shift towards mild disease characterized by the absence of draining tunnels, offering hope for long-term disease management and reduced burden for HS patients,” he added.